Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
380 studies found for:    "HIV Seronegativity" [CONDITION]
Show Display Options
Rank Status Study
21 Completed A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC-HIV MN120TMG (vCP205)
22 Completed A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: gp160 Vaccine (Immuno-AG)
23 Unknown  Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
Conditions: HIV Seronegativity;   HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59;   Biological: DNA-C2 + MVA-C;   Biological: DNA-C2 + MVA-C + gp140/MF59
24 Not yet recruiting CCTG 603: Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals (The iM-PrEPT Study)
Conditions: Patient Adherence;   HIV Seronegativity
Intervention: Behavioral: brief Motivational Interviewing
25 Active, not recruiting Pre-exposure Prophylaxis Accessibility Research and Evaluation 2
Conditions: PrEP Uptake;   HIV Seronegativity
Intervention: Behavioral: Informed Risk Score
26 Active, not recruiting CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM
Conditions: Patient Adherence;   HIV Seronegativity
Intervention: Device: SoC + iTab
27 Recruiting Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials
Conditions: HIV Infection;   HIV Seronegativity
Intervention:
28 Withdrawn Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Drug: Tenofovir DF
29 Completed Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC-HIV (vCP205)
30 Completed A Study of Male Rectal Samples in Preparation for Future Rectal Microbicide Trials
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Procedure: Flexible Sigmoidoscopy;   Procedure: Rectal Biopsy
31 Completed Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: MN rgp120/HIV-1 and A244 rgp120/HIV-1
32 Completed Long-Term Effects of HIV Exposure and Infection in Children
Conditions: HIV Infections;   HIV Seronegativity
Intervention:
33 Completed Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa
Conditions: HIV Infections;   HIV Seronegativity
Intervention:
34 Completed A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: MTP-PE/MF59;   Biological: Env 2-3
35 Completed A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: ALVAC(2)120(B,MN)GNP (vCP1452);   Biological: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1;   Biological: ALVAC-HIV MN120TMG (vCP205)
36 Withdrawn Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: Aluminum hydroxide;   Biological: QS-21;   Biological: MN rsgp120/HIV-1
37 Completed A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: rgp120/HIV-1MN;   Biological: rgp120/HIV-1 SF-2;   Biological: Placebo version of rgp120/HIV-1MN;   Biological: Placebo version of rgp120/HIV-1SF2
38 Completed A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: Env 2-3
39 Completed Carotid Artery Thickness in HIV Infected and Uninfected Adults
Conditions: HIV Infections;   HIV Seronegativity;   Atherosclerosis
Intervention:
40 Completed Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue
Conditions: HIV/AIDS;   HIV Infections
Interventions: Drug: darunavir;   Drug: Ritonavir;   Drug: Etravirine

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.